The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. 2021

Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China; China Academy of Chinese Medical Sciences, Beijing, 100700, China.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus causing serious human disease to spread across the world in the past 20 years, after SARS and Middle East respiratory syndrome. As of mid-September 2020, more than 200 countries and territories have reported 30 million cases of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, including 950,000 deaths. Supportive treatment remains the mainstay of therapy for COVID-19. The World Health Organization reported that four candidate drugs, including remdesivir, are ineffective or have little effect on COVID-19. According to China News, 90 % of Chinese patients with COVID-19 use traditional Chinese medicine (TCM), with an effectiveness rate of 80 %, and no deterioration in patient condition. We have compiled the direct evidence of TCM treatment for COVID-19 as of December 31, 2020. We describe the advantages of TCM in the treatment of COVID-19 based on clinical evidence and the required methods for its clinical use. TCM can inhibit virus replication and transcription, prevent the combination of SARS-CoV-2 and the host, and attenuate the cytokine storm and immune deficiency caused by the virus infection. The cooperation of many countries is required to establish international guidelines regarding the use of TCM in patients with severe COVID-19 from other regions and of different ethnicities. Studies on the psychological abnormalities in patients with COVID-19, and medical staff, is lacking; it is necessary to provide a complete chain of evidence to determine the efficacy of TCM in the related prevention, treatment, and recovery. This study aims to provide a reference for the rational use of TCM in the treatment of COVID-19.

UI MeSH Term Description Entries
D008516 Medicine, Chinese Traditional A system of traditional medicine which is based on the beliefs and practices of the Chinese culture. Chinese Medicine, Traditional,Chung I Hsueh,Traditional Medicine, Chinese,Zhong Yi Xue,Chinese Traditional Medicine,Traditional Chinese Medicine,Traditional Tongue Assessment,Traditional Tongue Diagnosis,Hsueh, Chung I,Tongue Assessment, Traditional,Tongue Diagnoses, Traditional,Tongue Diagnosis, Traditional,Traditional Tongue Assessments,Traditional Tongue Diagnoses
D004365 Drugs, Chinese Herbal Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China. Chinese Herbal Drugs,Plant Extracts, Chinese,Chinese Drugs, Plant,Chinese Plant Extracts,Extracts, Chinese Plant,Herbal Drugs, Chinese
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
May 2020, Complementary therapies in clinical practice,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
May 2020, Pharmacological research,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
November 2021, Acta pharmaceutica Sinica. B,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
January 2022, International journal of general medicine,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
May 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
January 2020, Chinese medicine,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
April 2020, Chinese herbal medicines,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
October 2020, The American journal of emergency medicine,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
October 2021, mBio,
Xuedong An, and YueHong Zhang, and Liyun Duan, and De Jin, and Shenghui Zhao, and RongRong Zhou, and Yingying Duan, and Fengmei Lian, and Xiaolin Tong
September 2022, Medicine in novel technology and devices,
Copied contents to your clipboard!